In a 43-year-old woman with intermittent mid-cycle spotting every 1–3 months, normal 4–5‑day menses, and dysmenorrhea occurring every other month, what is the appropriate evaluation and management?

Evaluation and Management of Mid-Cycle Spotting in a 43-Year-Old Woman

In this 43-year-old woman with intermittent mid-cycle spotting, you should first rule out structural and pathologic causes through focused evaluation, then provide reassurance if no underlying pathology is found, as mid-cycle spotting is often benign but requires exclusion of endometrial pathology given her age.

Initial Evaluation Approach

Key Clinical Assessment Points

The evaluation must distinguish between benign ovulatory bleeding and concerning pathology:

• Pregnancy status: Rule out pregnancy first, even with regular menses
• Contraceptive use: Determine if she's using any hormonal contraception (which would change the differential and management per 1)
• Pattern characteristics: Document timing relative to ovulation, volume, duration, and any associated symptoms
• Risk factors for endometrial pathology: Age >35 years (which she meets), obesity, chronic anovulation, unopposed estrogen exposure 2

Physical Examination

Perform a pelvic examination to assess for:

• Cervical lesions (polyps, ectropion, malignancy)
• Uterine size and contour (fibroids, adenomyosis)
• Adnexal masses
• Signs of infection

Critical caveat: Given her age of 43 years and the presence of dysmenorrhea, endometrial sampling should be strongly considered even if examination is normal 3, 2.

Diagnostic Workup

Imaging

Transvaginal ultrasound is the first-line imaging modality 4:

• Assess endometrial thickness and morphology
• Evaluate for structural lesions (polyps, fibroids, adenomyosis)
• Examine ovaries for masses or endometriomas

If transvaginal ultrasound cannot adequately visualize the endometrium due to body habitus, uterine position, or presence of fibroids/adenomyosis, MRI with diffusion-weighted imaging should be considered for complete endometrial assessment 4.

Endometrial Sampling

Endometrial biopsy is indicated in this patient because:

• She is >35 years old 2
• Mid-cycle spotting could represent endometrial pathology
• This is less invasive, safer, and lower cost than dilation and curettage 3

Important limitation: Endometrial biopsy sensitivity can be affected by focal lesions, so if clinical suspicion remains high despite negative biopsy, proceed to hysteroscopy 3.

Laboratory Testing

• Pregnancy test (β-hCG)
• Thyroid-stimulating hormone (hypothyroidism can cause menstrual irregularities) 2
• Consider coagulation studies if heavy bleeding is also present 2

Differential Diagnosis Priority

Most Likely Causes in This Age Group

1. Ovulatory spotting (benign mid-cycle bleeding from estrogen fluctuation)
2. Endometrial polyps (common structural cause) 4
3. Adenomyosis (especially with dysmenorrhea present) 5, 6
4. Endometriosis (given dysmenorrhea every other month) 7, 8
5. Perimenopause-related anovulation (increasingly common at age 43) 2
6. Endometrial hyperplasia or malignancy (must exclude given age)

Management Based on Findings

If No Structural Pathology Found

Reassurance is appropriate if workup is negative, but treatment options include:

• NSAIDs during bleeding days (5-7 days of treatment) 1

  • Reduces prostaglandin-mediated bleeding
  • Also addresses her dysmenorrhea 5, 8

• Hormonal contraceptives if contraception desired or symptoms persist 1:

  • Combined oral contraceptives regulate cycle and reduce dysmenorrhea
  • Progestin-only options if estrogen contraindicated

• Cyclic progestogen (if not seeking contraception):

  • Days 14-25 of cycle to stabilize endometrium

If Structural Lesions Identified

• Endometrial polyps: Hysteroscopic polypectomy
• Fibroids: Management based on size, location, symptoms
• Adenomyosis: NSAIDs, hormonal suppression, or definitive surgery if severe
• Endometriosis: Hormonal contraceptives are first-line 5

Addressing the Dysmenorrhea

The dysmenorrhea occurring every other month warrants specific attention:

• NSAIDs remain first-line treatment (ibuprofen 400-600mg or naproxen 500mg at onset of menses) 5, 8
• Combined hormonal contraceptives if NSAIDs insufficient 5, 8
• Consider secondary causes (endometriosis, adenomyosis) if not responding to initial therapy 5, 6

Common Pitfalls to Avoid

1. Don't dismiss symptoms as "just hormonal" without proper evaluation at age 43—endometrial sampling is warranted
2. Don't rely solely on ultrasound if it cannot adequately visualize the endometrium 4
3. Don't delay endometrial biopsy pending imaging results if clinical suspicion for pathology exists
4. Don't assume ovulatory bleeding without excluding structural causes first
5. Don't forget that dysmenorrhea may indicate endometriosis or adenomyosis, which could also explain the spotting 7

Follow-Up Strategy

• If initial workup negative and symptoms persist despite treatment: Consider hysteroscopy for direct visualization 3
• If symptoms worsen or pattern changes: Repeat evaluation
• If treatment fails: Reassess for secondary causes and consider referral to gynecology 1

The key principle: At age 43 with new or changing bleeding patterns, structural and malignant causes must be excluded before attributing symptoms to benign ovulatory dysfunction.